Prof. Borrelli | Safety, Tolerability and Short-term Efficacy of LM™ LLLT (PBM) for dry Age-related Macular Degeneration

Prof. Borrelli (MD, PhD) highlights LM™ Low-level Light Therapy (LM™ LLLT) as a novel, non-invasive treatment for dry Age-related Macular Degeneration (dAMD).

As lead investigator, he presents first results achieved in the LightWave I clinical trial and published in the September 2024 Issue of Springer’s Ophthalmology & Therapy Journal.

In the study, part of a longer longitudinal, double-masked multicentric trial effort, the safety, tolerability, and short-term efficacy of LM™ LLLT for patients with dAMD has been proven.

In this keynote, first presented at Euretina 2024, results and clinical cases demonstrate safety, tolerability and short-term efficacy (improved visual acuity and reduced drusen volume) of LM™ LLLT technology in the management of this retinal condition.

The event will be followed by a LIVE Q&A session with Espansione's Medical Affairs Team.

Can't join the live session? Sign up anyway, we'll send you the replay!